Antiviral drug allergy.
Milpied-Homsi B, Moran EM, Phillips EJ.
Immunol Allergy Clin North Am · research-article; review; journal article · DOI 10.1016/j.iac.2014.04.011 PUBLIKATIONSREGISTRET
Gå till forskningen.
Publikationsdata från Europe PMC och PubMed. Följ källhänvisningar från ämnesregistret till originalpublikationerna.
Publikationer som ChEBI hänvisar till för telaprevir. Visa hela publikationsregistret
En publikationsträff är inte en slutsats. Publikationslistan visar bibliografiska uppgifter. Eventuella forskningsutdrag visas separat med originalunderlag. En källhänvisning visar inte i sig effekt, dosering eller säkerhet.
Publikationer i urvalet
27 träffarThe effect of CYP3A inhibitors and inducers on the pharmacokinetics of telaprevir in healthy volunteers.
Garg V, Chandorkar G, Yang Y, Adda N, McNair L, Alves K, Smith F, van Heeswijk RP.
Br J Clin Pharmacol · research support, non-u.s. gov't; research-article; journal article · DOI 10.1111/j.1365-2125.2012.04345.xCharacterization of telaprevir treatment outcomes and resistance in patients with prior treatment failure: results from the REALIZE trial.
De Meyer S, Dierynck I, Ghys A, Beumont M, Daems B, Van Baelen B, Sullivan JC, Bartels DJ, Kieffer TL, Zeuzem S, Picchio G.
Hepatology · clinical trial, phase iii; research support, non-u.s. gov't; randomized controlled trial; journal article · DOI 10.1002/hep.25962Efficacy of telaprevir and boceprevir in treatment-naïve and treatment-experienced genotype 1 chronic hepatitis C patients: an indirect comparison using Bayesian network meta-analysis.
Cure S, Diels J, Gavart S, Bianic F, Jones E.
Curr Med Res Opin · comparative study; research support, non-u.s. gov't; systematic review; network meta-analysis; journal article · DOI 10.1185/03007995.2012.734798Safety of telaprevir for chronic hepatitis C virus infection: a meta-analysis of randomized controlled trials.
Qin H, Li H, Zhou X, Feng F, Shen Y, Tan H, Ye F, Xie Y.
Clin Drug Investig · meta-analysis; review; journal article · DOI 10.1007/bf03261920Telaprevir: pharmacokinetics and drug interactions.
Garg V, Kauffman RS, Beaumont M, van Heeswijk RP.
Antivir Ther · research support, non-u.s. gov't; review; journal article · DOI 10.3851/imp2356Interaction of the antiviral drug telaprevir with renal and hepatic drug transporters.
Kunze A, Huwyler J, Camenisch G, Gutmann H.
Biochem Pharmacol · journal article · DOI 10.1016/j.bcp.2012.07.032Cyclophilin inhibitors: a novel class of promising host-targeting anti-HCV agents.
Gallay PA.
Immunol Res · research-article; review; journal article; research support, n.i.h., extramural · DOI 10.1007/s12026-011-8263-5A practical guide for the use of boceprevir and telaprevir for the treatment of hepatitis C.
Jacobson IM, Pawlotsky JM, Afdhal NH, Dusheiko GM, Forns X, Jensen DM, Poordad F, Schulz J.
J Viral Hepat · review; journal article · DOI 10.1111/j.1365-2893.2012.01590.xMaximizing opportunities and avoiding mistakes in triple therapy for hepatitis C virus.
Barritt AS, Fried MW.
Gastroenterology · research-article; review; journal article; research support, n.i.h., extramural · DOI 10.1053/j.gastro.2012.02.013Hepatitis C viral evolution in genotype 1 treatment-naïve and treatment-experienced patients receiving telaprevir-based therapy in clinical trials.
Kieffer TL, De Meyer S, Bartels DJ, Sullivan JC, Zhang EZ, Tigges A, Dierynck I, Spanks J, Dorrian J, Jiang M, Adiwijaya B, Ghys A, Beumont M, Kauffman RS, Adda N, Jacobson IM, Sherman KE, Zeuzem S, Kwong AD, Picchio G.
PLoS One · research-article; research support, u.s. gov't, non-p.h.s.; journal article · DOI 10.1371/journal.pone.0034372Discovery of novel urea-based hepatitis C protease inhibitors with high potency against protease-inhibitor-resistant mutants.
Kazmierski WM, Hamatake R, Duan M, Wright LL, Smith GK, Jarvest RL, Ji JJ, Cooper JP, Tallant MD, Crosby RM, Creech K, Wang A, Li X, Zhang S, Zhang YK, Liu Y, Ding CZ, Zhou Y, Plattner JJ, Baker SJ, Bu W, Liu L.
J Med Chem · journal article · DOI 10.1021/jm201278qReview of boceprevir and telaprevir for the treatment of chronic hepatitis C.
Wilby KJ, Partovi N, Ford JA, Greanya E, Yoshida EM.
Can J Gastroenterol · review-article; review; journal article · DOI 10.1155/2012/751057Telaprevir.
Författaruppgift saknas
Prescrire Int · journal articleTelaprevir for chronic hepatitis C with genotype 1: a meta-analysis.
Dang SS, Wang WJ, Wang XF, Li YP, Li M, Jia XL, Wang Y, Liu E, Zhao S.
Hepatogastroenterology · meta-analysis; review; journal article · DOI 10.5754/hge11312Clinical relevance of detectable but not quantifiable hepatitis C virus RNA during boceprevir or telaprevir treatment.
Harrington PR, Zeng W, Naeger LK.
Hepatology · journal article · DOI 10.1002/hep.24791A review of drug interactions with boceprevir and telaprevir: implications for HIV and transplant patients.
Wilby KJ, Greanya ED, Ford JA, Yoshida EM, Partovi N.
Ann Hepatol · research support, non-u.s. gov't; review; journal article · DOI 10.1016/s1665-2681(19)31022-1Protease inhibitors: silver bullets for chronic hepatitis C infection?
Alkhouri N, Zein NN.
Cleve Clin J Med · review; journal article · DOI 10.3949/ccjm.79a.11082Efficacy and safety of telaprevir in patients with genotype 1 hepatitis C infection.
Cunningham M, Foster GR.
Ther Adv Gastroenterol · review-article; journal article · DOI 10.1177/1756283x11426895Telaprevir: a review of its use in the management of genotype 1 chronic hepatitis C.
Perry CM.
Drugs · review; journal article · DOI 10.2165/11208370-000000000-00000Telaprevir user's guide.
Liapakis AM, Jacobson I.
Liver Int · review; journal article · DOI 10.1111/j.1478-3231.2011.02708.x[Expert opinion on boceprevir- and telaprevir-based triple therapies of chronic hepatitis C].
Sarrazin C, Berg T, Cornberg M, Dollinger M, Ferenci P, Hinrichsen H, Klinker H, Kraus M, Manns M, Mauss S, Peck-Radosavljevic M, Schmidt H, Spengler U, Wedemeyer H, Wirth S, Zeuzem S.
Z Gastroenterol · review; journal article; english abstract · DOI 10.1055/s-0031-1282015Telaprevir: an oral protease inhibitor for hepatitis C virus infection.
Kim JJ, Culley CM, Mohammad RA.
Am J Health Syst Pharm · review; journal article · DOI 10.2146/ajhp110123The pharmacokinetic interaction between an oral contraceptive containing ethinyl estradiol and norethindrone and the HCV protease inhibitor telaprevir.
Garg V, van Heeswijk R, Yang Y, Kauffman R, Smith F, Adda N.
J Clin Pharmacol · controlled clinical trial; research support, non-u.s. gov't; clinical trial, phase i; journal article · DOI 10.1177/0091270011419855Safety, pharmacokinetics and resistant variants of telaprevir alone for 12 weeks in hepatitis C virus genotype 1b infection.
Yamada I, Suzuki F, Kamiya N, Aoki K, Sakurai Y, Kano M, Matsui H, Kumada H.
J Viral Hepat · research-article; clinical trial, phase i; journal article · DOI 10.1111/j.1365-2893.2011.01514.xDermatological side effects of hepatitis C and its treatment: patient management in the era of direct-acting antivirals.
Cacoub P, Bourlière M, Lübbe J, Dupin N, Buggisch P, Dusheiko G, Hézode C, Picard O, Pujol R, Segaert S, Thio B, Roujeau JC.
J Hepatol · review; journal article · DOI 10.1016/j.jhep.2011.08.006Telaprevir.
Författaruppgift saknas
Drugs R D · research-article; review; journal article · DOI 10.2165/11586020-000000000-00000